Huntington's Disease – Pipeline Review, H2 2012

Huntington's Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Huntington's Disease - Pipeline Review, H2 2012', provides an overview of the Huntington's Disease therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. 'Huntington's Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Huntington's Disease.
- A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Huntington's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Huntington's Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Huntington's Disease Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Huntington's Disease 9
Huntington's Disease Therapeutics under Development by Companies 11
Huntington's Disease Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Huntington's Disease Therapeutics – Products under Development by Companies 21
Huntington's Disease Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Huntington's Disease Therapeutics Development 25
Genzyme Corporation 25
NsGene A/S 26
GlaxoSmithKline plc 27
Ipsen S.A. 28
Cephalon, Inc. 29
Vertex Pharmaceuticals Incorporated 30
Hadasit Medical Research Services & Development Ltd 31
BrainStorm Cell Therapeutics Inc. 32
Neuralstem, Inc. 33
Living Cell Technologies Limited 34
NeuroSearch A/S 35
Cortex Pharmaceuticals, Inc. 36
Alnylam Pharmaceuticals, Inc 37
Prana Biotechnology Limited 38
Suven Life Sciences Ltd. 39
Raptor Pharmaceuticals Corp. 40
Oryzon 41
Ceregene, Inc. 42
Accera, Inc. 43
Wellstat Therapeutics Corporation 44
Aegera Therapeutics Inc. 45
Indus Biotech Private Limited 46
Siena Biotech S.p.A. 47
KineMed, Inc. 48
Omeros Corporation 49
N-Gene Research Laboratories, Inc. 50
Vybion, Inc. 51
Varinel, Inc. 52
Prosensa Therapeutics B.V. 53
Huntington's Disease – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 60
Drug For Huntington's Disease - Drug Profile 60
ALN-HTT - Drug Profile 61
OMS824 - Drug Profile 62
CERE-120 - Drug Profile 63
Selisistat - Drug Profile 66
PB-T2 - Drug Profile 68
RP103 - Drug Profile 69
INDUS815C - Drug Profile 72
AC-0523 - Drug Profile 73
NSD-726 - Drug Profile 74
Huntexil - Drug Profile 75
CX-929 - Drug Profile 77
VAR10300 - Drug Profile 79
AMT-090 - Drug Profile 81
NsG28 - Drug Profile 82
NsG32 - Drug Profile 83
NsG30 - Drug Profile 84
NsG33 - Drug Profile 85
NsG-33 - Drug Profile 87
NsG35 - Drug Profile 88
Zyprexa Velotab - Drug Profile 89
SUVN-502 - Drug Profile 90
Sunphenon EGCg - Drug Profile 92
Bendavia - Drug Profile 94
GSK356278 - Drug Profile 96
Strattera - Drug Profile 97
Citalopram - Drug Profile 98
Coenzyme Q10 - Drug Profile 99
UbiquinonE - Drug Profile 100
NurOwn Stem Cell Therapy - Drug Profile 101
PN-401 - Drug Profile 103
PRO289 - Drug Profile 105
GPCR antagonist Program - Drug Profile 106
Huntingtin Toxicity Inhibitor - Drug Profile 107
Creatine - Drug Profile 108
Huntington Disease Program - Drug Profile 110
GM-609 - Drug Profile 111
Antiarrhythmic Drug - Drug Profile 112
Phosphodiesterase Type 5 Inhibitors - Drug Profile 113
Cholesterol Absorption Inhibitor - Drug Profile 114
NTCell - Drug Profile 115
NG-094 - Drug Profile 117
NP03 - Drug Profile 118
INT41 - Drug Profile 120
OXD-4 - Drug Profile 121
Drug For Huntington's Disease - Drug Profile 122
JM6 - Drug Profile 123
Drug For Huntington's Disease - Drug Profile 124
Huntington's Disease Program - Drug Profile 125
BN82451 - Drug Profile 126
Huntington's Disease Therapeutics – Drug Profile Updates 127
Huntington's Disease Therapeutics – Discontinued Products 144
Huntington's Disease Therapeutics - Dormant Products 145
Huntington's Disease – Product Development Milestones 147
Featured News & Press Releases 147
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156

List of Tables
Number of Products Under Development for Huntington's Disease, H2 2012 13
Products under Development for Huntington's Disease – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Genzyme Corporation, H2 2012 29
NsGene A/S, H2 2012 30
GlaxoSmithKline plc, H2 2012 31
Ipsen S.A., H2 2012 32
Cephalon, Inc., H2 2012 33
Vertex Pharmaceuticals Incorporated, H2 2012 34
Hadasit Medical Research Services & Development Ltd, H2 2012 35
BrainStorm Cell Therapeutics Inc., H2 2012 36
Neuralstem, Inc., H2 2012 37
Living Cell Technologies Limited, H2 2012 38
NeuroSearch A/S, H2 2012 39
Cortex Pharmaceuticals, Inc., H2 2012 40
Alnylam Pharmaceuticals, Inc, H2 2012 41
Prana Biotechnology Limited, H2 2012 42
Suven Life Sciences Ltd., H2 2012 43
Raptor Pharmaceuticals Corp., H2 2012 44
Oryzon, H2 2012 45
Ceregene, Inc., H2 2012 46
Accera, Inc., H2 2012 47
Wellstat Therapeutics Corporation, H2 2012 48
Aegera Therapeutics Inc., H2 2012 49
Indus Biotech Private Limited, H2 2012 50
Siena Biotech S.p.A., H2 2012 51
KineMed, Inc., H2 2012 52
Omeros Corporation, H2 2012 53
N-Gene Research Laboratories, Inc., H2 2012 54
Vybion, Inc., H2 2012 55
Varinel, Inc., H2 2012 56
Prosensa Therapeutics B.V., H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Stage and Molecule Type, H2 2012 63
Huntington's Disease Therapeutics – Drug Profile Updates 131
Huntington's Disease Therapeutics – Discontinued Products 148
Huntington's Disease Therapeutics – Dormant Products 149
Huntington's Disease Therapeutics – Dormant Products (Contd..1) 150

List of Figures
Number of Products under Development for Huntington's Disease, H2 2012 13
Products under Development for Huntington's Disease – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 58
Assessment by Route of Administration, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 60
Assessment by Molecule Type, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 62